WO2019161472A1 - Método e kit para classificação de nódulos de tireoide - Google Patents
Método e kit para classificação de nódulos de tireoide Download PDFInfo
- Publication number
- WO2019161472A1 WO2019161472A1 PCT/BR2019/050053 BR2019050053W WO2019161472A1 WO 2019161472 A1 WO2019161472 A1 WO 2019161472A1 BR 2019050053 W BR2019050053 W BR 2019050053W WO 2019161472 A1 WO2019161472 A1 WO 2019161472A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hsa
- mir
- microrna
- thyroid
- discriminating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Definitions
- the present invention describes a method and kit for classifying thyroid nodules.
- the present invention is in the fields of Genetics and Molecular Biology.
- Thyroid nodules the main clinical manifestation of several thyroid diseases, are commonly observed in medical practice. Ultrasound studies in random populations show that up to 68% of the population may develop a thyroid nodule at some point in life.
- the problem is that between 15 and 30% of patients with punctured nodules receive a result known as an “indeterminate nodule” (“Bethesda III”, “Bethesda IV” or “Bethesda V”), ie the The pathologist who evaluated the punctured contents of the nodule does not have sufficient elements to discriminate the lesion between “benign” or “malignant”. In these cases, most international guidelines also recommend treatment through the surgical procedure for total or partial thyroid removal, since the risk of malignancy for undetermined lesions is relevant, ranging from 5 to 75%.
- Thyroid surgeries have perioperative mortality rates between 0.1 and 0.2%.
- Serious or permanent non-lethal complications including recurrent laryngeal nerve damage, hypocalcemia, re-bleeding, and infections, occur in 2 to 10% of surgeries.
- 34.7% of thyroidectomies performed at a university hospital present some of these complications, including hypoparathyroidism in 8.8% of cases.
- levothyroxine replacement will be necessary throughout life. In Brazil alone, there are an estimated 40,000 unnecessary thyroid surgeries per year.
- RNA genetic signatures have proven to be great tools in identifying benign lesions (Rule-out tests), with the clear objective of reducing unnecessary surgeries, as they have good results in sensitivity and negative predictive value (NPV).
- Another very desired feature for this type of test is the ability to be performed from the PAF material already collected from the patient, without the need to perform a new collection.
- the FNAB collection procedure is invasive, painful and stressful.
- analyzing exactly the same cells that were classified as “undetermined” is a clear and desired technical advantage.
- An important limitation of the currently available solutions is that there is no molecular examination for indeterminate nodules that is made from the sample already collected and achieves the minimum clinical performance values proposed by Vargas-Salas et al. considered both a rule-in and a rule-out test.
- microRNAs miRNAs - small non-coding single stranded 18 to 25 nucleotide RNAs participating in the process of regulating gene expression
- microRNAs small non-coding single stranded 18 to 25 nucleotide RNAs participating in the process of regulating gene expression
- WO2015175660A1 entitled “miRNA expression. in the classification of thyroid tumors, ”reveals methods of classification of thyroid tumors using microRNA molecules associated with specific thyroid tumors.
- WO2010129934A2 entitled “Methods and compositions for diagnosis of thyroid conditions” discloses compositions, kits and methods for molecular profiles and diagnostics of cancer, including cancer-associated genomic DNA markers. The paper reveals molecular profiles associated with thyroid cancer, methods for determining molecular profiles, and methods of analyzing results to provide a diagnosis.
- WO2013066678A1 entitled “MicroRNA expression profiling of thyroid cancer” discloses screening or diagnostic methods for thyroid cancer or a potential for developing thyroid cancer that include determining the expression levels of at least one miRNA selected from a specific group of miRNAs and compare the individual's miRNA expression levels with a control individual who has no thyroid cancer or nodular hyperplasia.
- Document W02012068400A2 entitled “MiRNAs for biomarkers for distinguishing benign from malignant thyroid neoplasms”, discloses methods and compositions for identifying a miRNA profile for a particular condition, such as thyroid nodules or thyroid cancer, and using the profile. in diagnosing a patient for a condition such as thyroid nodules or thyroid cancer.
- the invention is shown as an alternative to solve the various problems and drawbacks present in the existing undetermined thyroid nodule classification methods with the intention of advancing towards an ideal method by solving the problems of specificity, sensitivity, accessibility, convenience and cost for the classification of undetermined thyroid nodules.
- the present invention aims to solve the constant problems in the state of the art from an improved method for classifying thyroid nodules.
- the method of the invention comprises at least one microRNA expression level measurement step and at least one correlation step between the normalizing microRNA expression level and at least one discriminating microRNA; wherein said normalizing microRNA is selected in combinations of one to six within the group consisting of dme-miR-7, hsa-let-7a, hsa-let-7b, hsa-let-7e, hsa-let-7f, hsa -let-7g, hsa-miR-1, hsa-miR-101, hsa-miR-103, hsa-miR-106a, hsa-miR-106b, hsa-miR-10a, hsa-miR-1 179, hsa- miR-122, hsa-miR-125a-3p, hsa-m
- discriminating microRNA is selected from the group consisting of dme-miR-7, hsa-let-7a, hsa-let-7b, hsa-let-7e, hsa-let-7f, hsa-let- 7g, hsa-miR-1, hsa-miR-101, hsa-miR-103, hsa-miR-106a, hsa-miR-106b, hsa-miR-10a, hsa-miR-1 179, hsa-miR-122 hsa-miR-125a-3p, hsa-miR-125a-5p, hsa-miR-125b, hsa-miR-126b, hsa-miR-130b, hsa-miR-133a, hsa-miR-136 * , hsa- miR
- the present invention defines a thyroid nodule classification kit comprising:
- the inventive concept common to all claimed protection contexts is the solution presented to the problem of a more accurate classification of thyroid nodules, which includes one or more of the normalizing miRNAs and one or more of the discriminating miRNAs and / or form specific correlation between them.
- Figure 3 shows a detailed flowchart of the development and validation of microRNA selection, where 1 - 1205 Patients with FNAB results available (JAN / 2013 - JUL / 2016); 2 - 272 Patients with undetermined outcome Bethesda III, IV or V in FNAB; 3 - 212 Patients with> 2 FNAB slides and their postoperative tissue available; 4 - Review by two independent pathologists (FNAB slides and post surgical tissue); 5 - 192 Patients eligible for the study; 6 - 40 patients - postoperative tissue of BENIGN thyroid nodules that had been classified as undetermined (Bethesda III, IV or V) in FNAB; 7 - 40 patients - postoperative tissue of MALIGNAL thyroid nodules that had been classified as undetermined (Bethesda III, IV or V) in FNAB; 8 - RNA extraction; 9 - Pre-Amplification; 10 - cDNA; 1 1 - Real-Time PCR (TLDA Array Cards); 12 - Expression data from 39 B
- the present invention defines a method for classifying thyroid nodules comprising at least one step of measuring the level of expression of microRNAs and at least one step of correlation between the level of normalizing microRNA expression and at least one discriminating microRNA; wherein said normalizing microRNA is selected in combinations of one to six within the group consisting of dme-miR-7, hsa-let-7a, hsa-let-7b, hsa-let-7e, hsa-let-7f, hsa -let-7g, hsa-miR-1, hsa-miR-101, hsa-miR-103, hsa-miR-106a, hsa-miR-106b, hsa-miR-10a, hsa-miR-1 179, hsa- miR-122, hsa-miR-125a-3p, hsa-miR-125a-5p,
- discriminating microRNA is selected from the group consisting of dme-miR-7, hsa-let-7a, hsa-let-7b, hsa-let-7e, hsa-let-7f, hsa-let-7g, hsa- miR-1, hsa-miR-101, hsa-miR-103, hsa-miR-106a, hsa-miR-106b, hsa-miR-10a, hsa-miR-1 179, hsa-miR-122, hsa-miR -125a-3p, hsa-miR-125a-5p, hsa-miR-125b, hsa-miR-126b, hsa-miR-130b, hsa-miR-133a, hsa-miR-136 * , hsa-miR-
- said normalizing microRNA is selected from the group consisting of RNU48, hsa-miR-197, hsa-let-7b, hsa-miR-125a-5p, hsa-miR-103, hsa-let-7a , hsa-let-7e, hsa-miR-145, or combinations thereof.
- said discriminator microRNA is selected from the group consisting of hsa-miR-204, hsa-miR-152, hsa-miR-222, hsa-miR-181b, hsa-miR-146b, hsa-miR -155, hsa-miR-181a, hsa-miR-200b, hsa-miR-221 or combinations thereof.
- normalizing microRNAs and discriminating microRNAs are correlated from one or more of the following features:
- the normalizing microRNAs and discriminating microRNAs are correlated from one or more of the following groups:
- the thyroid nodule classification consists of at least one of: benign, malignant, medullary thyroid cancer, papillary thyroid carcinoma and its variants, thyroid follicular carcinoma and its variants, thyroid insular carcinoma, neoplasia Noninvasive follicular thyroid with nuclear features of papillary resemblance "NIFTP", goiter and its variants, adenomas and their variants, thyroid Hurthle cells and their thyroid variants and hyperplasias and their variants.
- NFTP noninvasive follicular thyroid with nuclear features of papillary resemblance
- goiter and its variants goiter and its variants
- adenomas and their variants thyroid Hurthle cells and their thyroid variants and hyperplasias and their variants.
- said discriminating microRNA is at least hsa-miR-375.
- the method comprises the steps of:
- step (c) correlate the data obtained in step (c) of the expression level of at least one normalizing microRNA and at least one discriminating microRNA.
- step (a) is performed by fine needle aspiration or biopsy; and / or step (c) is performed by a technique selected from the group consisting of RT-PCR, sequencing, microarray, fragment analysis, gel electrophoresis, mass spectrometry or combinations thereof; and / or step (d) is made by an algorithm.
- the method of the present invention works with either "fresh and liquid” samples of a new FNAB or with material extracted from already prepared and stained cytology slides and coverslip.
- said algorithm uses single and / or committee decision tree systems (RandonForest, ExtraTrees, C4.5, DecisionJungle, Boosted DecisionTrees, and others) to classify samples by analyzing the features generated by joint normalization of discriminator microRNAs by the normalizers.
- the method further comprises the steps of:
- step (b) a1) preparation of the sample collected in step (a) before performing step (b); b1) purifying the nucleic acids obtained in step (b);
- step (b2) cDNA synthesis from the nucleic acids obtained in step (b1); and optionally
- step (c) preamplification prior to step (c).
- the present invention provides a kit for classifying thyroid nodules, said kit comprising:
- normalizing microRNA is selected from the group consisting of dme-miR-7, hsa-let-7a, hsa-let-7b, hsa-let-7e, hsa-let-7f, hsa-let-7g, hsa-miR-1, hsa-miR-101, hsa-miR-103, hsa-miR-106a, hsa-miR-106b, hsa-miR-10a, hsa-miR-1 179, hsa-miR-122, hsa-miR-125a-3p, hsa-miR-125a -5p, hsa-miR-125b, hsa-miR-126, hsa-miR-130b, hsa-miR-133a, hsa-miR-136 * , hsa-miR-
- discriminating microRNA is selected from the group consisting of dme-miR-7, hsa-let-7a, hsa-let-7b, hsa-let-7e, hsa-let-7f, hsa-let-7g, hsa- miR-1, hsa-miR-101, hsa-miR-103, hsa-miR-106a, hsa-miR-106b, hsa-miR-10a, hsa-miR-1 179, hsa-miR-122, hsa-miR -125a-3p, hsa-miR-125a-5p, hsa-miR-125b, hsa-miR-126b, hsa-miR-130b, hsa-miR-133a, hsa-miR-136 * , hsa-miR-
- said normalizing microRNA is selected from the group consisting of RNU48, hsa-miR-197, hsa-let-7b, hsa-miR-125a-5p, hsa-miR-103, hsa-let -7a, hsa-let-7e, hsa-miR-145 or combinations thereof
- said discriminating microRNA is selected from the group consisting of hsa-miR-204, hsa-miR-152, hsa-miR-222, hsa-miR -181 b, hsa-miR-146b, hsa-miR-155, hsa-miR-181a, hsa-miR-200b, hsa-miR-221 or combinations thereof.
- the kit further comprises:
- the method and kit of the present invention provides a more accurate classification of thyroid nodule tumor type, either malignant or benign.
- the method of the present invention enables the use of either "fresh and liquid" specimen from a new FNAB or material extracted from already prepared and stained and coverslipped cytology slides, which provides a significant additional advantage over other existing methods. Examples - Embodiments
- the selection of the 10 normalizing candidates was made by standard deviation analysis.
- the 10 microRNAs with expression values (Ct) with the lowest standard deviation among all samples (benign and malignant) were pre-selected.
- Each of the 55 discriminator candidates (D) is normalized by each of the 175 normalization values (N) generated above.
- each discriminator generates 175 normalized values.
- Each of these values is called a feature.
- One or a feature is a value used in machine learning to separate classes.
- the concept used in the invention was to identify a set of features that have distinct values between benign and malignant.
- Filter-based metaheuristic methods were used to know which features best separate the benign and malignant classes. Examples include Pearson's correlation, Mutual Information score, Kendall's correlation coefficient, Spearman's correlation coefficient, Chi-squared statistic, Fisher score, and Count based feature selection.
- the present inventors observed that the top 10 features (ie, with the highest discriminating power between classes) were composed of these 17 microRNAs.
- Example 7 Evaluation of the use of microrna hsa-miR-375 as a biomarker of medullary thyroid carcinoma
- medullary thyroid carcinoma which represents about 5% -10% of primary thyroid tumors and may behave more aggressively than well-differentiated thyroid tumors, has been evaluated, in addition to presenting high incidence of metastases.
- CMT medullary thyroid carcinoma
- the identification of CMT at diagnosis in thyroid nodules may be extremely relevant for the definition of the correct surgical procedure to be performed, as well as suggesting investigation for other tumors and familial type 2 MEN syndrome.
- hsa-mir-375 and 8 other normalizing microRNAs were evaluated in 157 thyroid samples, 42 from CMT, 77 benign and 38 non-malignant.
- CMT 157 thyroid samples
- 77 are from patients with undetermined nodules and the analysis was performed by qPCR from cells extracted from FNA cytology slides.
- Another 80 samples were obtained from the ArrayExpress public database (E-GEOD-40807) from post-surgical tissue microarray analysis.
- the discriminatory potential of hsa-mir-375 was assessed by its fold-change relative to candidate microRNAs. normalizers.
- Results show that analysis of hsa-mir-375 expression against normalizing microRNAs showed that when fold-change is greater than or equal to 3.0, or greater than or equal to 2.5, this relationship has the potential to discriminate “CMT” vs “benign or malignant non-CMT” samples with 92% specificity, 78.6% sensitivity, 92% positive predictive value, 78.6% negative predictive value and 88.4% accuracy.
- hsa-mir-375 has a high potential to be used as a biomarker for CMT at diagnosis, including by analyzing its expression by qPCR in undetermined thyroid nodules from cells fixed in cytology slides. FNA, thus being able to objectively assist in medical decision-making about the best surgical approach and investigation to be performed.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/967,500 US20210214799A1 (en) | 2018-02-23 | 2019-02-22 | Method and kit for the classification of thyroid nodules |
BR112020018735-6A BR112020018735A2 (pt) | 2018-02-23 | 2019-02-22 | Método e kit para classificação de nódulos de tireoide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR102018003587-8A BR102018003587A2 (pt) | 2018-02-23 | 2018-02-23 | método e kit para detecção de tipo de tumor de tireoide |
BR102018003587-8 | 2018-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019161472A1 true WO2019161472A1 (pt) | 2019-08-29 |
Family
ID=67686632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2019/050053 WO2019161472A1 (pt) | 2018-02-23 | 2019-02-22 | Método e kit para classificação de nódulos de tireoide |
Country Status (3)
Country | Link |
---|---|
US (1) | US20210214799A1 (pt) |
BR (2) | BR102018003587A2 (pt) |
WO (1) | WO2019161472A1 (pt) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022133621A1 (es) * | 2020-12-24 | 2022-06-30 | Pontificia Universidad Católica De Chile | Método in vitro para el diagnóstico y predicción de la agresividad de cáncer de tiroides, las posibilidades y tipo de cirugía de precisión para la remoción del tumor en un sujeto; kit; reactivos para conformar dicho kit; uso de los reactivos y uso de marcadores moleculares parte del método |
WO2023283476A3 (en) * | 2021-07-09 | 2023-03-09 | Dana-Farber Cancer Institute, Inc. | Circulating microrna signatures for pancreatic cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015175660A1 (en) * | 2014-05-13 | 2015-11-19 | Rosetta Genomics, Ltd. | Mirna expression signature in the classification of thyroid tumors |
-
2018
- 2018-02-23 BR BR102018003587-8A patent/BR102018003587A2/pt not_active IP Right Cessation
-
2019
- 2019-02-22 US US16/967,500 patent/US20210214799A1/en active Pending
- 2019-02-22 WO PCT/BR2019/050053 patent/WO2019161472A1/pt active Application Filing
- 2019-02-22 BR BR112020018735-6A patent/BR112020018735A2/pt unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015175660A1 (en) * | 2014-05-13 | 2015-11-19 | Rosetta Genomics, Ltd. | Mirna expression signature in the classification of thyroid tumors |
Non-Patent Citations (5)
Title |
---|
KEUGTEON, X. M. ET AL.: "A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration", CLIN CANCER RES., vol. 18, no. 7, 2012, pages 2032 - 2038, XP055125465, doi:10.1158/1078-0432.CCR-11-2487 * |
LIU, X. ET AL.: "Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma", ONCOL REP., vol. 4, 2013, pages 1415 - 1420, XP055633122 * |
NIKIFOROVA, M. N. ET AL.: "MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility", J CLIN ENDOCRINOL METAB., vol. 93, no. 5, 2008, pages 1600 - 1608, XP002636292, doi:10.1210/jc.2007-2696 * |
SANTOS ET AL.: "Molecular classification of thyroid nodules with indeterminate cytology: development and validation of a highly sensitive and specific new miRNA-based classifier test using fine- needle aspiration smear slides", THYROID, vol. 28, no. 12, November 2018 (2018-11-01), pages 1618 - 1626, XP055633121 * |
YU , S. ET AL.: "Circulating MicroRNA Profiles as Potential Biomarkers for Diagnosis of Papillary Thyroid Carcinoma", THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 97, no. 6, 2012, pages 2084 - 2092 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022133621A1 (es) * | 2020-12-24 | 2022-06-30 | Pontificia Universidad Católica De Chile | Método in vitro para el diagnóstico y predicción de la agresividad de cáncer de tiroides, las posibilidades y tipo de cirugía de precisión para la remoción del tumor en un sujeto; kit; reactivos para conformar dicho kit; uso de los reactivos y uso de marcadores moleculares parte del método |
WO2023283476A3 (en) * | 2021-07-09 | 2023-03-09 | Dana-Farber Cancer Institute, Inc. | Circulating microrna signatures for pancreatic cancer |
Also Published As
Publication number | Publication date |
---|---|
BR102018003587A2 (pt) | 2020-07-07 |
US20210214799A1 (en) | 2021-07-15 |
BR112020018735A2 (pt) | 2021-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9708667B2 (en) | MiRNA expression signature in the classification of thyroid tumors | |
Youssef et al. | Accurate molecular classification of kidney cancer subtypes using microRNA signature | |
CN106795562B (zh) | Dna混合物中的组织甲基化模式分析 | |
US20140243240A1 (en) | microRNA EXPRESSION PROFILING OF THYROID CANCER | |
CA2945531C (en) | Mirna expression signature in the classification of thyroid tumors | |
EP4004238A1 (en) | Systems and methods for determining tumor fraction | |
Titov et al. | Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears | |
EP3652344A1 (en) | Dna targets as tissue-specific methylation markers | |
CN107513578A (zh) | 一种用于肺癌驱动基因及易感基因早筛的核酸质谱检测方法 | |
WO2019161472A1 (pt) | Método e kit para classificação de nódulos de tireoide | |
CN108823314B (zh) | 一种检测血浆游离dna中rnf213突变基因的试剂盒及其应用 | |
CN109628600A (zh) | 一种用于早期乳腺癌诊断的生物标志物 | |
EP3652342A1 (en) | Detecting tissue-specific dna | |
CN105349666B (zh) | 缺血性脑卒中miRNA标记物 | |
CN101298630A (zh) | 一种Solexa技术鉴定结肠癌病人血清中微小核糖核酸的方法 | |
WO2017046714A1 (en) | Methylation signature in squamous cell carcinoma of head and neck (hnscc) and applications thereof | |
CN107267600A (zh) | 一种富集brca1和brca2基因目标区域的引物、方法、试剂盒及其应用 | |
CN116157539A (zh) | 循环肿瘤核酸分子的多模态分析 | |
CN115772564B (zh) | 用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用 | |
WO2014078913A1 (en) | A method of detecting methylation | |
KR102534200B1 (ko) | 자궁경부암의 전이 진단용 바이오 마커 및 이의 용도 | |
CN115772566B (zh) | 用于辅助检测肺癌体细胞erbb2基因突变的甲基化生物标记物及其应用 | |
WO2016106643A1 (zh) | 检测非小细胞肺癌用药相关基因突变的引物及检测方法 | |
CN108018285A (zh) | 一种超敏感引物及其设计方法和应用 | |
CN115044671A (zh) | 可用于胃癌her2伴随诊断的基因甲基化标记物或其组合和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19757177 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020018735 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112020018735 Country of ref document: BR Free format text: EXPLIQUE A DIVERGENCIA NO NOME DE UM DOS INVENTORES (ROZANY MUCHA DUFLOTH) QUE CONSTA NA PUBLICACAO INTERNACIONAL WO 2019/161472 E O CONSTANTE DA PETICAO INICIAL NO 870200116474 . |
|
ENP | Entry into the national phase |
Ref document number: 112020018735 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200914 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19757177 Country of ref document: EP Kind code of ref document: A1 |